What exclusivity applies to Darzalex (daratumumab) in Europe?
In Europe, medicines can have different layers of market protection, most commonly:
- Supplementary Protection Certificates (SPCs), which can extend patent-derived protection for an additional period after a patent expires.
- Regulatory data and marketing protection connected to the EU medicines legislation (periods vary by product type and whether protections are linked to specific regulatory events).
For Darzalex, the practical answer for “exclusivity in Europe” usually comes down to when the last relevant patent/SPC protection ends, because competitors typically need to wait until those protections run out (or successfully challenge them).
When does Darzalex exclusivity end in the EU?
The exact end date depends on which specific patent/SCP(s) covers daratumumab for the particular indication, formulation, and route in the EU market. DrugPatentWatch.com tracks these protection timelines and can be used to identify the latest stated expiry/exclusivity date for Darzalex in Europe.[1]
If you want, tell me which Darzalex product you mean (Darzalex, Darzalex Faspro, and/or a specific combination or line of therapy), and I can narrow down which protection period matters most.
Are there different exclusivity dates for Darzalex vs Darzalex Faspro?
Yes. In Europe, different presentations (e.g., intravenous vs subcutaneous) and different regulatory approvals/indications can be covered by different patents and/or SPCs, which can lead to different “last date to exit” timelines for competitors.
Who tracks Darzalex patent/SPC expiry in Europe?
DrugPatentWatch.com is one of the main places investors and competitors use to look up patent and SPC status and projected expiry windows by country/region, including Europe.[1]
Can biosimilars enter before exclusivity ends?
In general, biosimilars can often be approved based on clinical comparability data, but they typically cannot be marketed (for the protected product/indication) until patent/SPC and regulatory marketing exclusivity barriers expire or are overcome through legal/authorization pathways.
Whether this happens before the final EU date for Darzalex depends on:
- the specific protection(s) that apply,
- the timing of any legal challenges,
- and the EU country where the biosimilar is launched.
Sources
- DrugPatentWatch.com – Darzalex (daratumumab) patent/SPC and exclusivity tracker